Description
Product Overview
The ProbeSeq Influenza B CRISPRDetect™ Guide RNA System provides validated CRISPR guide RNA constructs for programmable recognition of Influenza B viral RNA. The system targets conserved genomic regions of Influenza B to enable highly specific nucleic acid detection and rapid signal generation for molecular diagnostic development.
The system supports development of respiratory infection detection platforms, multiplex respiratory pathogen panels, point-of-care diagnostic technologies, microfluidic molecular detection systems, and CRISPR biosensor platforms. Guide RNAs are engineered to ensure strong target hybridization, efficient Cas enzyme activation, and stable performance across fluorescence, electrochemical, and lateral-flow detection formats.
CRISPR-Based Detection Advantages
CRISPR-based molecular detection provides a highly specific and programmable alternative to conventional nucleic acid detection methods such as PCR and antigen-based assays. Unlike traditional amplification techniques that require complex thermal cycling and laboratory infrastructure, CRISPR systems enable rapid, isothermal detection with single-nucleotide specificity and strong mismatch discrimination. Cas-mediated signal amplification generates high sensitivity while reducing false positives and background noise. Compared with antibody-based tests, CRISPR detection targets viral genetic material directly, allowing earlier detection and improved adaptability to emerging variants. The programmable nature of guide RNA design also enables rapid assay development, multiplex pathogen detection, and seamless integration with portable biosensors and microfluidic diagnostic platforms, making CRISPR technology particularly suitable for next-generation point-of-care and lab-on-chip diagnostic systems.
Molecular Detection Mechanism
Target recognition occurs through CRISPR guide RNA hybridization to complementary Influenza B RNA sequences. Upon target binding, Cas enzyme activation triggers collateral cleavage of reporter substrates or signal molecules, producing measurable detection output.
The system supports direct viral RNA detection or amplification-assisted workflows. When combined with RT-LAMP or recombinase polymerase amplification (RPA), detection sensitivity can reach very low viral copy numbers. Guide RNA design promotes stable Cas complex formation while minimizing non-specific activation.
Target Design Strategy
Guide RNA sequences are selected from conserved Influenza B genomic regions such as hemagglutinin (HA), neuraminidase (NA), and nonstructural (NS) gene segments to ensure robust detection across circulating strains.
Design optimization prioritizes high sequence specificity and mismatch discrimination, broad lineage coverage including Victoria and Yamagata lineages, minimal cross-reactivity with Influenza A and other respiratory viruses, thermodynamic stability of guide–target hybridization, and compatibility with multiplex respiratory detection panels. Custom lineage-specific probes are available.
Assay Workflow Integration
The CRISPRDetect™ system supports flexible workflows including RNA extraction or crude sample preparation, optional nucleic acid amplification, CRISPR reaction assembly, and signal readout using compatible detection platforms.
Detection can be performed using fluorescence readers, electrochemical biosensors, lateral-flow systems, or microfluidic devices. Typical reaction input volumes range from approximately 5–20 µL depending on assay configuration.
System Components
Sequence-validated CRISPR guide RNA probes
Target sequence reference documentation
Recommended reaction conditions and buffers
Reporter compatibility guidance
Handling and storage instructions
Custom multiplex respiratory panels available upon request.
Platform Compatibility
Cas12-based detection systems
Cas13 RNA detection workflows
Fluorescent reporter assays
Electrochemical nucleic acid sensors
Lateral-flow detection platforms
Microfluidic cartridge systems
Automated molecular diagnostic devices
Portable point-of-care testing platforms
Guide RNA architecture supports integration with lab-on-chip and capillary-driven microfluidic technologies.
Performance Characteristics
High sequence selectivity, rapid target recognition kinetics, low background activation, stable performance under isothermal conditions, multiplex detection capability, and scalability for high-throughput assay development. Performance depends on enzyme selection and assay configuration.
Technical Specifications
Detection target: Influenza B viral RNA
Guide RNA length: optimized for Cas system compatibility
Enzyme compatibility: Cas12 / Cas13 platforms
Format options: Lyophilized or RNase-free solution
Typical concentration range: 10–100 µM
Reaction temperature range: assay-dependent
Storage: –20 °C recommended
Quality Assurance
Sequence verification, purity and integrity testing, functional activity validation, RNase contamination control, and manufacturing quality review are performed for each batch. Certificate of Analysis available upon request.
Research Applications
Respiratory infection diagnostic development
Multiplex pathogen detection research
CRISPR biosensor engineering
Microfluidic molecular diagnostics
Rapid viral detection technology development
Point-of-care respiratory testing platforms
Environmental and surveillance monitoring
Storage and Handling
Store at –20 °C under RNase-free conditions. Lyophilized format provides enhanced stability during transport and storage. Avoid repeated freeze–thaw cycles for solution format.
